Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.33 Consensus Target Price from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given an average rating of “Hold” by the fifteen brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $21.3750.

KROS has been the topic of several recent research reports. Weiss Ratings restated a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 1st. Oppenheimer reissued an “outperform” rating and issued a $27.00 target price (up previously from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. Wedbush upped their target price on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Wells Fargo & Company lowered their price target on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Finally, Bank of America boosted their price objective on shares of Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a research report on Friday, November 28th.

Keros Therapeutics Price Performance

Shares of KROS opened at $21.69 on Wednesday. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37. The stock has a market cap of $660.89 million, a price-to-earnings ratio of 14.08, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89. The firm has a 50 day simple moving average of $16.28 and a 200-day simple moving average of $15.14.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.93. The firm had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.Keros Therapeutics’s quarterly revenue was up 3585.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.41) EPS. On average, equities analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $84,975,125.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $95,659,436.00. The SEC filing for this sale provides additional information. Insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. CWM LLC grew its holdings in Keros Therapeutics by 10,157.7% in the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after buying an additional 2,641 shares during the period. Tower Research Capital LLC TRC grew its holdings in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares during the period. Farther Finance Advisors LLC purchased a new stake in Keros Therapeutics in the third quarter valued at approximately $47,000. SG Americas Securities LLC acquired a new position in Keros Therapeutics during the third quarter worth approximately $103,000. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in Keros Therapeutics by 29.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock worth $110,000 after purchasing an additional 1,892 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.